GlassScriptPhysician profile
Jennifer Cantrell
NPI 1568884831
$874.94
in general payments reported to CMS, 2019-2025
20 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $137 · 2023: $179 · 2024: $185 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.81 | 2021-2025 | |
| Medline Industries LP | $76.60 | 2023 | |
| Nestle Healthcare Nutrition INC. | $60.75 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $56.57 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $50.59 | 2025 | Jynarque |
| Daiichi Sankyo INC. | $48.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.76 | 2023-2024 | |
| Mindray Ds USA, INC. | $30.32 | 2023 | A7 Anesthesia System |
| Novo Nordisk INC | $25.01 | 2025 | Ozempic, Rybelsus |
| Myovant Sciences INC. | $22.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.47 | 2025 | |
| Abbott Laboratories | $20.77 | 2021 | |
| Vivus LLC | $20.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.61 | 2024 | Entyvio |
| Exeltis, USA INC. | $18.46 | 2024 | Slynd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $17.02 | 2024 | |
| Travere Therapeutics, INC. | $16.73 | 2025 | |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Shingrix, Arexvy |
| Cardiva Medical, INC. | $14.37 | 2023 | Cardiva Vascade 6/7f Vcs |
| Smith+Nephew, INC. | $12.78 | 2023 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cantrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.